Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
1. Overview of head and neck cancer management
2. The role of immunotherapy and molecularly targeted therapies in head and neck cancer
3. Targeting the PI3K/mTOR pathway
4. Autophagy inhibition to sensitize HNC to radiation and chemotherapy
5. Overcoming head and neck cancer stem cells
6. TAM Family proteins and therapy resistance
7. Eph/Ephrin family proteins and theapy resistance
8. Metabolic reprogramming to modulate therapeutic sensitivity
9. FGFR and cMET
10. Targeting GPCRs in HNC
11. Improving the response to immunotherapy
12. Chk1/2 inhibition in radiation and cetuximab resistance
Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic.
The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance.
This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites.
- Provides key scientific background for clinicians when developing novel clinical trials and important examples for basic scientists of the types of work required to move a concept from the lab to the clinic
- Presents consistent pathway diagrams in each chapter, thus making it easier to understand complicated pathways
- Includes chapter summaries of the critical next steps needed to move studies from their current state into practice changing clinical data
Cancer researchers; oncologists; graduate students
- No. of pages:
- © Academic Press 2020
- 5th October 2019
- Academic Press
- Hardcover ISBN:
- eBook ISBN:
Dr. Bonavida is internationally renowned by his expertise and various publications in the field of tumor cell sensitization to chemotherapy and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. He was the first individual to co-organize the first international workshop on NO and Cancer with Dr. Jean-François Jeannin in Paris. Subsequently, they co-organized three additional conferences on the same topic. The last fourth workshop was held in March in Sevilla, Spain with Dr. Muntane, and the proceedings were published in Redox Biology recently. These conferences focus on NO and derivatives in cancer and their therapeutic applications in resistant cancer.
Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, USA
Dr. Kimple completed his MD, PhD in Pharmacology, and residency in Radiation Oncology at the University of North Carolina. He is an Associate Professor of Human Oncology at the University of Wisconsin School of Medicine and Public Health where he is a member of the Multidisciplinary Head and Neck Program and the Wisconsin Head and Neck Cancer SPORE Grant. He runs a translational research lab focused on understanding the molecular basis of therapeutic resistance in head and neck cancer.
Associate Professor, Department of Human Oncology, UW Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA